Pharmaceuticals Portfolio Financials
| FPHAX Fund | USD 26.00 0.21 0.80% |
Pharmaceuticals |
Please note that past performance is not an indicator of the future performance of Pharmaceuticals Portfolio, its manager's success, or the effectiveness of its strategy. The performance results shown here may have been adversely or favorably impacted by events and economic conditions that may not prevail in the future. Therefore, you must use caution to infer that these results indicate any fund, manager, or strategy's future performance. Investment returns and principal value will fluctuate so that investors' shares, when sold, may be worth more or less than their original cost.
Pharmaceuticals Portfolio Fund Summary
Pharmaceuticals Portfolio competes with Fidelity Advisor, Fidelity Advisor, Fidelity Advisor, Fidelity Advisor, and Fidelity Advisor. The fund normally invests at least 80 percent of assets in companies engaged in the research, development, manufacture, sale, or distribution of pharmaceuticals and drugs of all types. It invests in domestic and foreign issuers. The fund invests primarily in common stocks. It uses fundamental analysis of factors such as each issuers financial condition and industry position, as well as market and economic conditions to select investments. The fund is non-diversified.Specialization | Health, Large Growth |
| Instrument | USA Mutual Fund View All |
| Exchange | NMFQS Exchange |
| ISIN | US3163904424 |
| Business Address | Fidelity Select Portfolios |
| Mutual Fund Family | Fidelity Investments |
| Mutual Fund Category | Health |
| Benchmark | NYSE Composite |
| Phone | 800 544 8544 |
| Currency | USD - US Dollar |
You should never invest in Pharmaceuticals Portfolio Pharmaceuticals without having analyzed available financial metrics that contribute to the net asset value (NAV) of the fund. Do not rely on someone else's analysis or guesses about the future performance of Pharmaceuticals Mutual Fund, because this is throwing your money away. Analyzing the key information contained in Pharmaceuticals Portfolio's prospectus and an annual reports, can give you an edge over other investors and help to ensure that your investments perform well for you.
Pharmaceuticals Portfolio Key Financial Ratios
Generally speaking, Pharmaceuticals Portfolio's financial ratios allow both analysts and investors to convert raw data from Pharmaceuticals Portfolio's financial statements into concise, actionable information that can be used to evaluate the performance of Pharmaceuticals Portfolio over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Pharmaceuticals Portfolio reports annually and quarterly.Pharmaceuticals Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Pharmaceuticals Portfolio's current stock value. Our valuation model uses many indicators to compare Pharmaceuticals Portfolio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Pharmaceuticals Portfolio competition to find correlations between indicators driving Pharmaceuticals Portfolio's intrinsic value. More Info.Pharmaceuticals Portfolio Pharmaceuticals is one of the top funds in price to earning among similar funds. It is one of the top funds in price to book among similar funds fabricating about 0.11 of Price To Book per Price To Earning. The ratio of Price To Earning to Price To Book for Pharmaceuticals Portfolio Pharmaceuticals is roughly 9.10 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Pharmaceuticals Portfolio by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Pharmaceuticals Portfolio's Mutual Fund. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Pharmaceuticals Portfolio's earnings, one of the primary drivers of an investment's value.Pharmaceuticals Portfolio Systematic Risk
Pharmaceuticals Portfolio's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Pharmaceuticals Portfolio volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Pharmaceuticals Portfolio correlated with the market. If Beta is less than 0 Pharmaceuticals Portfolio generally moves in the opposite direction as compared to the market. If Pharmaceuticals Portfolio Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Pharmaceuticals Portfolio is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Pharmaceuticals Portfolio is generally in the same direction as the market. If Beta > 1 Pharmaceuticals Portfolio moves generally in the same direction as, but more than the movement of the benchmark.
Pharmaceuticals Portfolio April 19, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Pharmaceuticals Portfolio help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Pharmaceuticals Portfolio Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Pharmaceuticals Portfolio Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Pharmaceuticals Mutual Fund price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Pharmaceuticals Portfolio's daily price indicators and compare them against related drivers.
| Downside Deviation | 0.8636 | |||
| Information Ratio | 0.0503 | |||
| Maximum Drawdown | 4.53 | |||
| Value At Risk | (1.20) | |||
| Potential Upside | 1.56 |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Pharmaceuticals Portfolio Pharmaceuticals. Also, note that the market value of any mutual fund could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Pharmaceuticals Portfolio information on this page should be used as a complementary analysis to other Pharmaceuticals Portfolio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.